ESC 2024: Study highlights potential for Novartis to differentiate in HF space
Pharmaceutical Technology
AUGUST 31, 2024
There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations and mortality.
Let's personalize your content